<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174732</url>
  </required_header>
  <id_info>
    <org_study_id>API-A006-CL-B</org_study_id>
    <nct_id>NCT01174732</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study of A006 DPI, in Adult Asthma Patients</brief_title>
  <official_title>Phase II Study Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Cross-over and Dose-ranging Study of A006 DPI, Albuterol Inhalation Powder, in Adult Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, active- and placebo-controlled, single-dose, seven-arm, crossover
      and dose-ranging design. This study aims to evaluate the efficacy and initial safety
      profiles, and to identify the optimum dose of A006, from a select dose-range for future
      clinical PK/PD and Phase III studies. This study is to be conducted in generally healthy,
      adult subjects who have mild-to-moderate persistent asthma for at least 6 months prior to
      Screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>5, 20, 40, 60, 90; 120, 180, 240, and 360 minutes post-dose.</time_frame>
    <description>Area under the curve (AUC) of post-dose FEV1 percentage changes from the Pre-dose Baseline. The primary analysis of the primary endpoint is to compare the AUC0-t of FEV1, between the A006 treatments and the Placebo Control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Effect</measure>
    <time_frame>0 to 360 minutes</time_frame>
    <description>Time to onset of bronchodilator effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Response</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>peak bronchodilator response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Duration of effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>0 - 360 minutes</time_frame>
    <description>Bronchodilatory Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Tremor</measure>
    <time_frame>within 5 min. prior to dosing and 50 and 360 min post-dose.</time_frame>
    <description>Evaluation of hand tremor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>within 15 min. prior to dosing, and 30, 90 and 360 min post-dose.</time_frame>
    <description>Pulse, heartrate, respirations, blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 lead ECG</measure>
    <time_frame>within 15 min. prior to dosing and at 50 and 360 min postdose.</time_frame>
    <description>12-lead ECG for routine and QT/QTc evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Work</measure>
    <time_frame>within 15 min. prior to dosing, and 30 and 120 min. postdose</time_frame>
    <description>Collect blood samples (~5 mL) for serum glucose and K+ tests</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Asthma</condition>
  <condition>Bronchospasm</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proventil 90 mcg/inhalation, 2 inhalations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proventil 90 mcg/inhalation, 4 inhalations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol inhalation powder</intervention_name>
    <description>A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol inhalation powder</intervention_name>
    <description>A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation</description>
    <arm_group_label>T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol inhalation powder</intervention_name>
    <description>A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol inhalation powder</intervention_name>
    <description>A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, lactose inhalation carrier</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol inhalation aerosol</intervention_name>
    <description>albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations</description>
    <arm_group_label>R1</arm_group_label>
    <other_name>Proventil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol inhalation aerosol</intervention_name>
    <description>albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations</description>
    <arm_group_label>R2</arm_group_label>
    <other_name>Proventil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With mild-to-moderate persistent asthma for at least 6 months and having used inhaled
             beta-agonist for asthma control;

          -  Must demonstrate response to beta 2 agonist by Reversing;

          -  Must demonstrate ability to use DPI;

          -  Females of child-bearing potential must be non-pregnant, non-lactating, and practicing
             a clinically acceptable form of birth control;

          -  Additional Criteria

        Exclusion Criteria:

          -  Smoking history of ≥ 10 pack-years, or having smoked within 6 months;

          -  Upper respiratory tract infections

          -  Asthma exacerbations;

          -  Known intolerance or hypersensitivity to any of the ingredients of the study drug or
             Proventil®;

          -  Use of prohibited drugs or failure to observe the drug washout restrictions;

          -  Having been on other clinical drug/device studies in the last 30 days;

          -  Other Criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safety Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Amphastar Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amphastar Site 0001</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 0007</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 0008</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphastar Site 0039</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <disposition_first_submitted>April 17, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 17, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 19, 2017</disposition_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>bronchospasm</keyword>
  <keyword>COPD</keyword>
  <keyword>chronic respiratory disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Bronchial Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

